ConvaTec announces the appointment of Ken Berger to the position of CEO effective March 6, 2012
Feb 21, 2012
David I. Johnson to step down as CEO and resign from
Board of Directors
ConvaTec, a world-leading developer and marketer of
innovative medical technologies for community and hospital care,
today announces that Ken Berger will assume the position of CEO,
ConvaTec, and will be appointed to the ConvaTec Board of
Berger joins ConvaTec from Thermo Fisher Scientific where he
spent the last ten years, most recently as Senior Vice President
and Group resident of the Specialty Diagnostics Group, a global $2
billion high-value diagnostics business. "We are excited to
have Ken take over the helm of ConvaTec," said Toni Weitzberg,
Chairman of the Board of Directors for ConvaTec. "His track
record of building highly profitable businesses, combined with
diverse global experience and a history of building strong
leadership teams is well suited to take ConvaTec to the next level
of performance excellence."
"I am pleased to work with Nordic Capital and Avista Capital
Partners as CEO of ConvaTec," said Berger, "and I look forward to
working with the ConvaTec team to realize the incredible potential
of this business."
This appointment follows the mutual agreement between David I.
Johnson and the ConvaTec Board of Directors that he will step down
as CEO, effective March 5, 2012. "Dave successfully managed
the carve-out from Bristol Myers Squibb Co. and created an
independent global company with a strong platform for growth."
stated Weitzberg, "The Board thanks him for his service in leading
ConvaTec over the past six years, and for his dedication to the
Company for over twelve years."
"I am proud to leave this fine organization with a strengthened
financial foundation, renewed growth momentum; and of course, a
continued commitment to the company mission." said Johnson.
"I am confident that the entire organization is ready to take
ConvaTec to even greater heights."
Over the next sixty days, Johnson will work with the Board and
his successor to ensure an orderly transition of leadership.
ConvaTec is a leading developer and marketer of innovative
medical technologies that have helped improve the lives of millions
of people worldwide. With four key focus areas - Ostomy Care, Wound
Therapeutics, Continence and Critical Care, and Infusion Devices -
ConvaTec products support healthcare professionals from the
hospital to the community health setting. For more information,
please visit www.convatec.com.
About Nordic Capital Private Equity Funds
Since the start in 1989, Nordic Capital Private Equity Funds
have invested in large and medium sized companies, primarily in
Northern Europe. Through committed ownership and by targeting
strategic development and operational improvements, Nordic Capital
creates value in its investments. The funds invest in companies in
Northern Europe and in selected investment opportunities
internationally. They are based in Jersey, Channel Islands, and are
advised by the NC Advisory companies in Sweden, Denmark, Finland,
Norway, Germany and the UK. Additional information about Nordic
Capital is available through its corporate website, www.nordiccapital.com.
Back to news listings >